Recent clinical data highlights how melatonin formulary removal in Alberta, Canada, shifted psychotropic utilization trends. Consequently, healthcare providers are currently re-evaluating insomnia management strategies. This retrospective review tracked inpatient and pediatric units before and after the policy change. Although melatonin use fell sharply, the overall psychotropic utilization also decreased by 13.5% across various clinical sites.

Data analysis revealed that total psychotropic use dropped from 731.83 to 632.78 defined daily doses per 1000 patient-days. Therefore, the removal did not trigger a simple substitution effect for more potent sedative-hypnotics in all cases. For instance, benzodiazepine and Z-drug utilization decreased by 8.4% and 8.8%, respectively. However, these drug classes still represent the highest utilization rates for managing sleep disturbances in hospital settings.

Impact of Melatonin Formulary Removal on Antidepressants

Furthermore, the study noted a significant rise in antidepressant utilization. Antidepressant use increased by 17.3% following the delisting of melatonin. This shift indicates that clinicians might be choosing sedating antidepressants as safer alternatives for insomnia. Nevertheless, the researchers caution that these trends vary significantly across different sites and geographic zones. Because the results are site-specific, they may not apply universally to all clinical institutions.

How does melatonin removal lead to more benzodiazepine use?

According to the recent data, benzodiazepine use actually saw a modest decrease of 8.4% after the formulary change. Consequently, the policy did not result in an immediate spike in these high-risk medications, suggesting a broader reduction in sedative use.

Which drug class saw the highest increase in utilization?

The study found a 17.3% relative increase in the utilization of antidepressants. This suggests a therapeutic shift toward using this class for managing insomnia symptoms in inpatient and pediatric populations when melatonin is unavailable.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Chan RRD et al. Impact of delisting melatonin from a health-system formulary on psychotropic utilization. Australas Psychiatry. 2026 Apr 28. doi: 10.1177/10398562261446491. PMID: 42050379.

Wright A, Diebold J, Otal J, et al. The Effect of Melatonin on Benzodiazepine Discontinuation and Sleep Quality in Adults Attempting to Discontinue Benzodiazepines: A Systematic Review and Meta-Analysis. Drugs Aging. 2015;32(12):1009-1018. doi:10.1007/s40266-015-0322-5.

NSW Clinical Excellence Commission. NSW Medicines Formulary Information—Use of Melatonin in NSW Health Facilities. 2023. Available from: https://www.cec.health.nsw.gov.au.